Literature DB >> 24483952

Long-term episomal transgene expression from mitotically stable integration-deficient lentiviral vectors.

Hanna Kymäläinen1, J Uwe Appelt, Frank A Giordano, Angela F Davies, Caroline M Ogilvie, Sherif G Ahmed, Stephanie Laufs, Manfred Schmidt, Juergen Bode, Rafael J Yáñez-Muñoz, George Dickson.   

Abstract

Nonintegrating gene delivery vectors have an improved safety profile compared with integrating vectors, but transgene retention is problematic as nonreplicating episomes are progressively and rapidly diluted out through cell division. We have developed an integration-deficient lentiviral vector (IDLV) system generating mitotically stable episomes capable of long-term transgene expression. We found that a transient cell cycle arrest at the time of transduction with IDLVs resulted in 13-45% of Chinese hamster ovary (CHO) cells expressing the transgene for over 100 cell generations in the absence of selection. The use of a scaffold/matrix attachment region did not result in improved episomal retention in this system, and episomes did not form after transduction with adeno-associated viral or minicircle vectors under the same conditions. Investigations into the episomal status of the vector genome using (1) linear amplification-mediated polymerase chain reaction followed by deep sequencing of vector-genome junctions, (2) Southern blotting, and (3) fluorescent in situ hybridization strongly suggest that the vector is not integrated in the vast majority of cells. In conclusion, we have developed an IDLV procedure generating mitotically stable episomes capable of long-term transgene expression. The application of this approach to stem cell populations could significantly improve the safety profile of a range of stem and progenitor cell gene therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24483952      PMCID: PMC4027990          DOI: 10.1089/hum.2013.172

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  37 in total

1.  Non-viral S/MAR vectors replicate episomally in vivo when provided with a selective advantage.

Authors:  S P Wong; O Argyros; C Coutelle; R P Harbottle
Journal:  Gene Ther       Date:  2010-08-26       Impact factor: 5.250

Review 2.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

3.  QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis.

Authors:  J-U Appelt; F A Giordano; M Ecker; I Roeder; N Grund; A Hotz-Wagenblatt; G Opelz; W J Zeller; H Allgayer; S Fruehauf; S Laufs
Journal:  Gene Ther       Date:  2009-04-23       Impact factor: 5.250

4.  Cell cycle dependent histone dynamics of an episomal non-viral vector.

Authors:  Sina Rupprecht; Hans J Lipps
Journal:  Gene       Date:  2009-03-21       Impact factor: 3.688

5.  Minicircle performance depending on S/MAR-nuclear matrix interactions.

Authors:  Sandra Broll; André Oumard; Kathrin Hahn; Axel Schambach; Juergen Bode
Journal:  J Mol Biol       Date:  2009-12-29       Impact factor: 5.469

6.  Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.

Authors:  Taeyoung Koo; Alberto Malerba; Takis Athanasopoulos; Capucine Trollet; Luisa Boldrin; Arnaud Ferry; Linda Popplewell; Helen Foster; Keith Foster; George Dickson
Journal:  Hum Gene Ther       Date:  2011-05-25       Impact factor: 5.695

7.  The functional role of S/MARs in episomal vectors as defined by the stress-induced destabilization profile of the vector sequences.

Authors:  Aristeidis Giannakopoulos; Eleana F Stavrou; Ioannis Zarkadis; Nicholas Zoumbos; Adrian J Thrasher; Aglaia Athanassiadou
Journal:  J Mol Biol       Date:  2009-02-25       Impact factor: 5.469

8.  Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk.

Authors:  Janka Mátrai; Alessio Cantore; Cynthia C Bartholomae; Andrea Annoni; Wei Wang; Abel Acosta-Sanchez; Ermira Samara-Kuko; Liesbeth De Waele; Ling Ma; Pietro Genovese; Martina Damo; Anne Arens; Kevin Goudy; Timothy C Nichols; Christof von Kalle; Marinee K L Chuah; Maria Grazia Roncarolo; Manfred Schmidt; Thierry Vandendriessche; Luigi Naldini
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

9.  A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype.

Authors:  Brian L Ellis; Matthew L Hirsch; Jenny C Barker; Jon P Connelly; Robert J Steininger; Matthew H Porteus
Journal:  Virol J       Date:  2013-03-06       Impact factor: 4.099

10.  Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord.

Authors:  H Peluffo; E Foster; S G Ahmed; N Lago; T H Hutson; L Moon; P Yip; K Wanisch; V Caraballo-Miralles; G Olmos; J Lladó; S B McMahon; R J Yáñez-Muñoz
Journal:  Gene Ther       Date:  2012-10-18       Impact factor: 4.184

View more
  12 in total

1.  Construction of recombinant adenovirus containing picorna-viral 2A-peptide sequence for the co-expression of neuro-protective growth factors in human umbilical cord blood cells.

Authors:  E E Garanina; Y O Mukhamedshina; I I Salafutdinov; A P Kiyasov; L M Lima; H J Reis; A Palotás; R R Islamov; A A Rizvanov
Journal:  Spinal Cord       Date:  2015-10-06       Impact factor: 2.772

Review 2.  Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing.

Authors:  Benjamin E Epstein; David V Schaffer
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 3.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

4.  The β-globin Replicator greatly enhances the potential of S/MAR based episomal vectors for gene transfer into human haematopoietic progenitor cells.

Authors:  Eleana F Stavrou; Vassileios M Lazaris; Aristeidis Giannakopoulos; Eirini Papapetrou; Alexandros Spyridonidis; Nikolas C Zoumbos; Antonis Gkountis; Aglaia Athanassiadou
Journal:  Sci Rep       Date:  2017-01-20       Impact factor: 4.379

Review 5.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05

6.  Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion.

Authors:  Yongxiang Zheng; Fei Yu; Yiming Wu; Longlong Si; Huan Xu; Chuanling Zhang; Qing Xia; Sulong Xiao; Qi Wang; Qiuchen He; Peng Chen; Jiangyun Wang; Kazunari Taira; Lihe Zhang; Demin Zhou
Journal:  Nucleic Acids Res       Date:  2015-03-12       Impact factor: 16.971

7.  Impact of Different Promoters on Episomal Vectors Harbouring Characteristic Motifs of Matrix Attachment Regions.

Authors:  Xiao-Yin Wang; Jun-He Zhang; Xi Zhang; Qiu-Li Sun; Chun-Peng Zhao; Tian-Yun Wang
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

8.  Engineering dynamic cell cycle control with synthetic small molecule-responsive RNA devices.

Authors:  Kathy Y Wei; Christina D Smolke
Journal:  J Biol Eng       Date:  2015-11-20       Impact factor: 4.355

9.  The IS2 Element Improves Transcription Efficiency of Integration-Deficient Lentiviral Vector Episomes.

Authors:  Sabina Sánchez-Hernández; Alejandra Gutierrez-Guerrero; Rocío Martín-Guerra; Marina Cortijo-Gutierrez; María Tristán-Manzano; Sandra Rodriguez-Perales; Laura Sanchez; Jose Luis Garcia-Perez; Jesus Chato-Astrain; Ricardo Fernandez-Valades; Ana Belén Carrillo-Galvez; Per Anderson; Rosa Montes; Pedro J Real; Francisco Martin; Karim Benabdellah
Journal:  Mol Ther Nucleic Acids       Date:  2018-08-18       Impact factor: 8.886

Review 10.  The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective.

Authors:  Parviz Mammadzada; Pablo M Corredoira; Helder André
Journal:  Cell Mol Life Sci       Date:  2019-12-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.